Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvu

Publicado 15/04/2015 8:01:12CET

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References


1) Lixiana(R) (edoxaban) Prescribing Information. Daiichi Sankyo
(Switzerland) AG. 2015.
2) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial
fibrillation. N Engl J Med. 2013;369(22):2093-2104.
3) Büller H, et al. Edoxaban versus warfarin for the treatment of symptomatic
venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
4) Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ.
2005;330(7485):238-43.
5) Pavlovic N, et al. Atrial fibrillation - European and Swiss perspectives.
Cardiovasc Med. 2014;17(6):167-170.
6) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of the European Society of Cardiology
(ESC). Eur Heart J. 2010;31(19):2369-2429.
7) Krijthe BP, et al. Projections on the number of individuals with atrial
fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35
):2746-2751.
8) Cohen A, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost.
2007;98(4):756-764.
9) Daiichi Sankyo press release - Daiichi Sankyo Launches New Formulation of
LIXIANA(R) 60 mg Tablets (edoxaban) in Japan. 8 Dec 2014. Available
at:http://www.daiichisankyo.com/media_investors/media_relations...
. [Last accessed: April 2015].
10) Daiichi Sankyo press release - SAVAYSA(TM) (edoxaban) Now Available in U.S.
Pharmacies. 9 February 2015. Available
at:http://www.daiichisankyo.com/media_investors/media_relations...
. [Last accessed: April 2015].


Contact
Daria Munsel (European Media)
Daiichi Sankyo Europe GmbH
Edoxaban Comm. & Product PR Europe
Phone: +49-89-7808728

Sandra Lingk (Germany, Austria, Switzerland Media)
Daiichi Sankyo Deutschland GmbH
Product PR Manager DACH
Phone: +49-89-7808732

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación